Moderna Inc. shares surged 57.27 percent before Wednesday’s opening bell after the company’s personalized cancer vaccine met two primary goals in a Phase 3 melanoma trial. The stock climbed to $99.02 from Tuesday’s closing price of $62.96, marking the first positive late stage result ever recorded for an mRNA cancer vaccine and easing one of […]

The postModerna stock soars 57% on cancer vaccine winappeared first onRolling Out.